An analysis of drug approvals in India over past 5 years
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20243037Keywords:
CDSCO, New drug development, FDC, Drug approval, ATC groupAbstract
Background: Drug development is a tedious process and takes a long time for approval by regulatory authorities. With time, Indian authorities have revised rules and regulations for conducting clinical trials as well as for the marketing of drugs, impacting the number of drugs being approved.
Method: The information about drug approvals from 2019–2023 was obtained from the CDSCO website. The single drug products were classified into 14 main anatomical therapeutic chemical (ATC) groups, while Fixed Dose Combinations (FDCs) were classified based on the system they act upon. Descriptive statistical analysis was done. The findings of our observational study were expressed as absolute numbers and percentages.
Results: Total 362 drugs were approved. Out of these, 135 were single drug products, and the rest were FDCs. The highest & lowest number of drugs were approved in the year 2022 and 2019 respectively. Maximum single drug product approvals were seen in Category L-antineoplastic and immunomodulating agents, while maximum FDC approvals were for drugs acting on the endocrine system.
Conclusion: There is a rising trend of approval for FDCs. The pattern of single drug products approval flattened over the years, coinciding with the implementation of new rules and regulations.
Metrics
References
Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimers Dement Transl Res Clin Interv. 2017;3(4):651–7.
Kataria BC, Bhavsar VH, Donga BN. Contemplation on approved drugs in India from 1999 through 2011. Asian J Pharm Clin Res. 2012;5(3):25-9.
Roy AM, Jones R, Mathew A. A comparative study of cancer drug approvals in India and high-income countries. J Cancer Policy. 2022;1:33.
Lahiry S, Sinha R, Choudhury S, Mukherjee A, Chatterjee S. Paradigm shift in clinical trial regulations in India. Indian J Rheumatol. 2018;13(1):51.
Karve AV, Sheth AP, Perveen SS. An analysis of drug approvals in india over past 10 years. J Res Educ Indian Med. 2014;20(3-4):141-52.
Bandarapalle K, Kumarachari RK, Sri KT, Neeraja B, Likhitha C, Chaitanya K, et al. A Review on regulatory affairs and regulatory requirements for drug approval. Future J Pharm Health Sci. 2024;4(1):26–38.
Ministry of Health and Family Welfare. Govt of India. Notification. The Gazette of India: Extraordinary, Part II, Section 3, Subsection (I), New Delhi. 2019. Available at: https:// cdsco. gov.in/ opencms/ export.
Chawan V, Gawand K, Phatak A, Badwane S. An overview of drugs approved in India from 1999 through 2015. Int J Basic Clin Pharmacol. 2015;697–700.
Chaudhry S. Fixed dose combinations in India- what a way to go! Indian J Pharm Pharmacol. 2023;10(1):45–9.
Approved New Drugs. 2024. Available at: https://cdsco.gov.in/opencms/opencms/en/Approval.
ATCDDD-Guidelines. 2024. Available at: https://atcddd.fhi.no/atc_ddd_index. Accessed on 17th March 2024.
Singh J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. J Pharmacol Pharmacother. 2015;6(3):185–7.
India-Sample Registration System (SRS)-cause of death in India 2017-2019. Available at: https://censusindia.gov.in/nada/index.
Gupta Y, Ramachandran S. Fixed dose drug combinations: issues and challenges in India. Indian J Pharmacol. 2016;48(4):347.
The Central Drugs Standard Control Organization (CDSCO). Mashelkar committee report. 2012. Available at: http://cdsco.nic.in. Accessed on 17th March 2024.
Downloads
Published
How to Cite
Issue
Section
